author-photo

Talha Badar

Mayo Clinic

15

Papers

8

Citations

Citation Trend

Filter By

Papers (9) Sort By

Journal Conference Others

Multicenter Analysis of Treatment and Outcomes for Patient with TP53 Mutated AML in the Era of Novel Therapies; Significant Impact of Allogeneic Stem Cell Transplantation on Survival

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Intensive Induction Regimens after Deferring Initial Therapy for Mantle Cell Lymphoma Are Not Associated with Improved Survival.

2021 European Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (0)
Do histone deacytelase inhibitors and azacitidine combination hold potential as an effective treatment for high/very-high risk myelodysplastic syndromes?

2021 Expert Opinion on Investigational Drugs
- Talha Badar
- Ehab Atallah
Show All
- Source
- Cite
- Save
Citations (0)
Characteristics and Clinical Outcome of Patients with Clonal Cytopenias of Undetermined Significance: A Large Retrospective Multi-Center International Study

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms.

2021 Blood Advances
Show All
- Source
- Cite
- Save
Citations (0)
Clinical Characteristics and Prognosis of Thirty-Three Patients with Myeloid Neoplasms and DDX41 Mutation: Mayo Clinic Experience

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) As Consolidation Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for Treatment of Relapsed Acute Lymphoblastic Leukemia (ALL)

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
DDX41 Variant of Unknown Significance (VUS) Have Distinct Clinical and Diagnostic Features but Are Associated with Similar Prognosis and Co-Mutation Patterns As Pathogenic DDX41 : Analysis of the Mayo Clinic (MC) Myeloid Next-Generation Sequencing (NGS) Cohort

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Comparing the Efficacy of Cyclophosphamide Versus Lenalidomide in Combination with Bortezomib for Newly Diagnosed Multiple Myeloma Treatment: A Systematic Review

2020 Blood
Show All
- Source
- Cite
- Save
Citations (0)